Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HaRyPOT: Radiotherapy + PD-1 Inhibitor in MSS CRLM
NCT06045286Phase 1Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zimberelimab in metastatic colorectal cancer (mCRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective Response Rate at 12 months. Started Sep 2023; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06045286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045286.